Objective To characterize, among European and Han Chinese populations, the genetic predictors of maculopapular exanthema (MPE), a cutaneous adverse drug reaction common to antiepileptic drugs.
Idiosyncratic cutaneous adverse drug reactions (cADRs) can have a genetic predisposition. The HLA-B*15:02 allele is a predictor of carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) in individuals of Han Chinese and Southeast Asian descent, while a recent meta-analysis suggests that the allele is also a significant risk factor for oxcarbazepine-, phenytoin-, and lamotrigine-induced SJS/TEN. 1, 2 However, the association with HLA-B*15:02 does not extend to the milder but more common maculopapular exanthema (MPE) phenotype, and the allele is specific to individuals of Asian descent, limiting clinical utility across populations. 3, 4 HLA-A*31:01 has been confirmed as a transethnic risk factor for carbamazepineinduced cADRs, with the allele observed across populations of European, Japanese, and Korean descent. [5] [6] [7] [8] Recently, HLA-A*24:02 has been shown to associate with SJS in Han Chinese patients, irrespective of causal drug studied. 9 Genetic variation beyond the major histocompatibility locus has also been associated with cADRs. The CYP2C9*3 allele correlates with phenytoin hypersensitivity in Han Chinese from Taiwan, 10 with a similar effect reported in a Thai population. 11 However, a genome-wide association study (GWAS) of lamotrigine and phenytoin-induced cADRs in Europeans did not detect significant predictors. 12 A summary of the associated genetic risk variants for cADRs in various populations is provided in table e-1 (links.lww.com/WNL/A56).
The EpiPGX Consortium was established to identify genetic markers of epilepsy treatment response. The International League Against Epilepsy Complex Genetics Consortium (ILAE-CGC) facilitates the discovery of genetic variants influencing epilepsy predisposition. 13 The EPIGEN consortium is a worldwide epilepsy genetics research framework and the Canadian Pharmacogenomics Network for Drug Safety (CPNDS) is an active surveillance network focused on identifying genomic markers of severe adverse drug reactions (ADRs) in children and adults.
14 Collaboration among these consortia has provided detailed phenotypes and genotypes for over 15,000 epilepsy cases, for the investigation of antiepileptic drug (AED)-induced MPE.
Availing of the joint resources of EpiPGX, ILAE-CGC, EPIGEN, and CPNDS, this study aimed to characterize, among European and Han Chinese populations, the genetic predictors of MPE, a cutaneous ADR common to particular AEDs. Specifically, we set out to test the following hypotheses: (1) whether population-specific genetic variants predict MPE; (2) whether transethnic genetic variants predict MPE; (3) whether population-specific genetic variants predict AEDspecific MPE; and (4) whether transethnic genetic variants predict AED-specific MPE.
Methods
Standard protocol approvals, registrations, and patient consents All study participants provided written, informed consent for genetic analysis. Local institutional review boards approved study protocols at each contributing site.
Study design
We conducted a retrospective case-control study in individuals of European and Han Chinese ethnicity. Participants were exposed to carbamazepine, lamotrigine, phenytoin, or oxcarbazepine. Our analyses were structured to test genetic variants for association with MPE within and across both of the broad ancestral groups, through logistic regression of genotype dosage and subsequent meta-analysis of regression coefficients. We tested for association with (1) aromatic AED-induced MPE vs controls tolerant to at least 3 aromatic AEDs, (2) carbamazepine-induced MPE vs carbamazepine-tolerant controls, (3) lamotrigine-induced MPE vs lamotrigine-tolerant controls, and (4) phenytoin-induced MPE vs phenytointolerant controls. Due to small sample size, oxcarbazepinerelated MPE was not analyzed as an individual case cohort.
Cohorts and phenotype definition
Epilepsy cohorts from the ILAE-CGC, EpiPGX, and EPIGEN Consortia were included in the discovery GWAS metaanalysis (table 1) . A European-descent replication cohort was assembled from sites in Brazil, Canada (via CPNDS), Liverpool, and other sites across the United Kingdom. Cases were defined as having MPE attributed to carbamazepine, lamotrigine, phenytoin, or oxcarbazepine as determined by their clinician, occurring within 3 months of initiation and resolving upon dose reduction or AED withdrawal. Control patients trialed carbamazepine, lamotrigine, phenytoin, or oxcarbazepine for at least 3 months without reporting a cADR. Epilepsyspecific patient demographics are presented in table e-2 (links. lww.com/WNL/A56).
Genotyping and imputation
Genotyping of a subset of EpiPGX samples was performed at deCODE Genetics (Reykjavik, Iceland) using Illumina (San Diego, CA) OmniExpress-12 v1.1 and OmniExpress-24 v1.1 single nucleotide polymorphism (SNP) arrays. The remainder of samples were genotyped locally using various Illumina beadchip SNP arrays, details of which are published elsewhere. 13 Genotyping and imputation quality control is described in appendix e-1 (links.lww.com/WNL/A57).
Study power
We estimated that the study had 80% power to detect a genetic predictor of relative risk (approximated to odds ratio) ≥3 with an allele frequency ≥2% and an α level of 1.25 × 10 . Power for AED-specific and population-specific analyses are detailed in appendix e-1 (links.lww.com/WNL/A57).
Statistical analyses
Association analyses were conducted within the European and Asian subgroups using an additive logistic regression model. To account for genotype uncertainty, SNPTEST was used to apply a missing data likelihood score model that included sex, clinical site, and 5 principal components as covariates to control for bias and population stratification. 15 Fixed effects meta-analyses were conducted across the European and Asian subgroups using the software package METAL, applying genomic control correction within cohorts. 16 The threshold for statistical significance was set at 1.25 × 10 −8 , reflecting an empirical Bonferroni correction for 4 tests, of the standard 5 × 10 −8 genome-wide significance threshold. Conditional association analysis was performed on loci containing significant markers to establish whether other genetic variants in the region (1 Mb upstream and downstream) were independently associated with MPE. The conditional threshold for significance was set at 5 × 10
, based on a genome-wide estimation of 10,000 imputed variants per 2 MB region. 13 We applied the Stouffer z trend test to the combined results from the discovery and replication cohorts.
Confirmatory genotyping
Where an association signal satisfied the threshold for significance, additional genotyping and resequencing were performed in a subset of patients and results were compared with imputation dosage files. The variant rs78239784 was confirmed by Sanger sequencing in 100 patients from the original discovery cohort. For the purpose of replication, we genotyped the rs78239784 variant in an independent cohort of 13 phenytoin-induced MPE cases and 88 phenytointolerant controls.
Results

Cohort description
In total, 375 MPE cases and 1,321 controls satisfied our criteria for inclusion in the discovery analyses (see Methods and table 1). There were 16 patients with cross-reactivity to 2 or more aromatic AEDs, 8 of whom were hypersensitive to carbamazepine and lamotrigine. Genome-wide array data for 323 cases and 1,321 controls were available for analysis. Broad European or Han Chinese ancestry was assigned to each participant according to principal components analysis (figure e-1, links.lww.com/WNL/A55).
Genome-wide association analysis of broad aromatic AED-induced MPE After quality control (see appendix e-1, figure e-2, links.lww. com/WNL/A55, for details), 3,693,290 variants remained for analysis in the European dataset and 4,402,554 variants in the Han Chinese dataset. We only considered autosomal SNPs in our analyses. To test hypothesis (1) , that population-specific genetic markers predispose to MPE, a logistic regression analysis of all MPE cases was performed separately in the European and Han Chinese ancestral subgroups. We did not observe any genome-wide significant markers for MPE due to any aromatic AED in either Europeans or Han Chinese. The study was powered to detect an effect of relative risk >3.5 in the European cohort and >5 in the Han Chinese.
To test hypothesis (2) , that transethnic genetic markers predispose to MPE, a fixed-effects meta-analysis of the association results for European and Han Chinese ancestral subgroups was performed. We did not observe any genome-wide significant markers for MPE shared among European or Han Chinese subgroups ( figure 1A ). This analysis was powered to detect an effect size >3. figure 2 ). Conditioning on rs78239784 did not reveal additional variants in this locus that were independently contributing to phenytoin-induced MPE. Using 1000 Genomes Phase III European population data, rs78239784 was found to be in complete linkage disequilibrium with rs35274867 (r 2 = 1 and D' = 1), a missense variant coding for an asparagine to tyrosine substitution at amino acid 1,050 of the complement factor H (CFH) gene. The missense variant was not present in our association results, as it was filtered during quality control because the imputation score was <0.95. The imputation accuracy of the top variant rs78239784 was confirmed in our cohort via Sanger sequencing and TaqMan approaches. Of 100 samples tested, a 100% concordance rate was found between imputed and resequenced genotypes. Within the Han Chinese subgroup, no significant associations were found between autosomal SNPs or HLA alleles and AED-specific MPE. Summary results for known risk loci in our dataset were scrutinized and are presented in table 2. None of these loci was even nominally significant (p > 0.05) in the Han Chinese subgroup.
In order to test hypothesis (4) , that transethnic genetic markers predispose to AED-specific MPE, we meta-analyzed p values from association results for carbamazepine, lamotrigine, and phenytoin individually, across European and Han Chinese ancestral subgroups. There were no shared genomewide significant markers among our meta-analyses of AEDspecific MPE ( figure 1, B-D) .
Replication of CFHR4 signal
To replicate the association with phenytoin-induced MPE in an independent cohort, the variant rs78239784 was genotyped in self-reported European-descent cases and controls 
Discussion
We detected a strong association between variants in the complement factor H regulatory pathway and phenytoininduced MPE in a European-descent patient population. The presence of the associated genotype increases risk for MPE 6-fold. Our results indicate that risk variants for MPE tend to be drug-specific and population-specific.
These results point to the regulators of complement activation gene cluster as a genetic locus contributing to the onset of hypersensitivity to phenytoin. The most significant variant in our European subgroup analysis, rs78239784 (c.59-2448T>G), tags the missense variant rs35274867 (p. N1050Y) in CFH, suggesting aberrant complement activation as a potential causal mechanism in a subset of phenytoinsensitive individuals. According to data from the Exome Aggregation Consortium, CFH N1050Y has an allele frequency of approximately 2% in Europeans, 3% in African subpopulations, less than 1% in South Asians, and is almost invariant in East Asians. 17 Given the absence of this allele in East Asian populations, the lack of an association between the CFH locus and MPE in our Han Chinese cohort is unsurprising. We propose that population-specific, independent rare variants of large effect may explain a proportion of MPE cases, a similar paradigm to the rare variant model demonstrated in Crohn disease and ulcerative colitis. 18 CFH N1050Y has previously been associated with type 2 diabetes-associated end-stage kidney disease in an African American cohort. 19 Defects in CFH-related proteins are also associated with overactivation of the complement immune system and can lead to atypical hemolytic-uremic syndrome, C3 glomerulopathy, basal laminar drusen, immunoglobulin A nephropathies, and systemic lupus erythematosus. 20 Further, genetic variants in CFHR4 and CFH are associated with risk for agerelated macular degeneration. 21 We did not detect these symptoms among N1050Y carriers. While it is unclear whether phenytoin directly interacts with circulating CFHrelated proteins, it does not specifically increase serum complement levels. 22 Our findings offer an expanded insight into the role of the complement alternative pathway in hypersensitivity to AEDs.
Phenytoin is still used as a first-line treatment for epilepsy in many settings and is listed on the WHO list of essential medicines. 23 Epidemiologic data on prescriptions of AEDs for epilepsy in the United Kingdom show that, in 2008, phenytoin accounted for 18% of all treated person-years in epilepsy and was most frequently used in the elderly. 24 Therefore, a clinically useful prognostic test for phenytoin-induced cutaneous ADRs in European-ancestral individuals would be welcome. The sensitivity of the CFHR4 variant as a prognostic marker is 16% and the specificity is 97%, which corresponds to a positive likelihood ratio of 5.93 (95% CI 2.8-12.6) and a negative likelihood ratio of 0.86 (95% CI 0.8-0.9). Assuming the pretest probability of the ADR is 5%, a positive test for this marker increases the probability of MPE to phenytoin sixfold to 30%, while a negative test reduces the probability marginally to 4.3%. There are an estimated 6 million people with epilepsy in Europe, which means approximately 90,000 people are at-risk carriers of this mutation. 25 We estimate that 208 (95% CI 103-431) patients of European ancestry would need to be screened to prevent one case, based on a previously reported formula, 26 which corresponds to an absolute risk reduction of 0.005 (95% CI 0.002-0.009). As a comparison, it is estimated that 442 Han Chinese patients would be needed to screened for HLA-B*15: 02 in order to prevent a single carbamazepine-induced SJS/ TEN case. We would suggest that the clinical utility and costeffectiveness of implementing preemptive screening be evaluated through a prospective study.
We did not replicate the association between CYP2C9*3 (rs1057910) and MPE in our cohort, irrespective of ethnicity or AED. This is not surprising given that the original association with phenytoin in Han Chinese was largely driven by SJS/TEN cases, which were excluded from this analysis. We did, however, detect a nonsignificant enrichment of CYP2C9*3 (p = 0.08) among the European phenytoin- induced 10 Notably, 2 CYP2C9*3 carriers among the phenytoin-induced MPE cases were also heterozygous for the CFHR4 variant while only 3 of 560 controls were jointly heterozygous. The frequency of CYP2C9*3 differs between controls from European and Han Chinese subgroups in our study, which is in accordance with background population frequency reported in the Exome Aggregation Consortium (European: 7%, East Asian: 3%). While our results do not support a significant effect of CYP2C9*3 in MPE, larger cohorts including severe cADR cases may resolve the extent of the association across populations.
HLA-A*31:01 was the most strongly associated marker with carbamazepine-induced MPE in Europeans in this study. Forty-three of the 95 cases studied here were also included in the discovery publication, 8 but the effect of the allele remains significant when we restrict to new cases only (p = 4 × 10 −7 ), thus providing an additional independent replication of the initial finding. We confirm that HLA-B*15:02 is not associated with carbamazepine-induced MPE in Han Chinese, and no novel signals emerged for carbamazepine-induced MPE in either population. No significant predictors of lamotrigineinduced MPE were observed in either population tested. HLA-A*24:02 was not significantly associated with lamotrigine-induced MPE in either of the European or Han Chinese ancestral subgroups; rather this allele was observed to be more frequent among our lamotrigine-tolerant controls.
Our meta-analyses did not reveal any significant transethnic genetic markers for MPE due to any AED. There were considerably more European-descent patients in this analysis than any other ethnicity, and we recognize this as a limitation of the study. Analysis of non-European cohorts is warranted. A second limitation of our study was the low number of Han Chinese lamotrigine-related MPE cases, relative to Europeandescent cases. Therefore we cannot conclusively rule out genetic predictors of modest effect size for MPE to lamotrigine in Han Chinese or other non-European descent populations. We recognize that our replication cohort for phenytoin is small and comprises self-reported ancestral Europeans. Since we did not have full genotype array data for these individuals, we relied on Fisher exact test for calculating significance rather than logistic regression with correction for principal components. Additional studies of larger sample size are required to further characterize the association, improve the estimation of the risk effect size, and determine the prognostic ability and economics of screening for this marker. Finally, as this study was not powered to investigate MPE attributed to oxcarbazepine due to low sample size, further investigation is warranted.
We have identified a genetic predictor for a common adverse reaction to phenytoin in European-descent patients, adding a new pharmacogenetic marker for potential use in the treatment of epilepsy. This finding adds to the list of genetic Representative risk alleles from previous genome-wide association study findings and this report for antiepileptic drug-induced skin rash studies (CBZ, LTG, and PHT) were assessed for association in our study. predictors of hypersensitivity to anticonvulsant therapy and opens up a new avenue for understanding the biology underlying cutaneous adverse reactions. This finding can advance genetic testing in the clinic as it expands the array of genetic tests available to aid clinicians in reducing overall rates of discontinuation due to adverse events and improving patient safety. 
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